DLL3 CAR-T Therapy Targeting Brain Tumors
Shenzhen Geno-Immune Medical Institute
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic pontine or midline gliomas (DIPG or DMG). Another goal of the study is to learn more about the function of the anti-DLL3 CAR-T cells and their persistency in patients.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- NOT_YET_RECRUITING
- phase
- PHASE1, PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 30
- sponsor
- Shenzhen Geno-Immune Medical Institute
- conditions
- Glioblastoma of Cerebellum
- interventions
- BIOLOGICAL: 4SCAR DLL3 T cells
- start date
- 2027-06-01
- start date type
- ESTIMATED
- primary completion date
- 2028-05-31
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07180927
- Published
- Sep 18, 2025
- Updated
- Sep 1, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07180927
- Categories
- Glioblastoma of Cerebellum
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials